NovImmune Secures Over $56M to Buy Back Two mAbs from Merck...

New financing helps company reacquire autoimmune disease candidates, further its seven in-house mAbs, and ready for strategic partnerships.

Paladin and Isotechnika Combine Forces to Advance Latter’s Immunosuppressant

Paladin will own 19% of new entity formed to further development. Paladin Labs and Isotechnika entered a strategic alliance to advance development and commercialization of...

Sanofi Pasteur’s Flu Vaccine Manufacturing Plant Gets FDA Nod

Facility will add 100 million doses to firm’s current 50 million dose capacity. FDA approved Sanofi Pasteur’s new manufacturing facility for the production of seasonal...

Alethia Licenses Preclinical Cancer mAbs for Drug and Diagnostic Development

Family of compounds from NRC-BRI target secreted clusterin. Alethia Biotherapeutics is licensing exclusive, worldwide therapeutic and diagnostic rights to clusterin-specific antibodies from the NRC Biotechnology...

Avastin Approved in Fourth Tumor Type

FDA decision for glioblastoma comes after drug missed endpoint in Phase III early-stage colon cancer setting. Genentech and Roche’s Avastin portfolio received some better news...

Novotech and ETI Ally to Harness Indian Clinical Research Opportunities

Joint venture offers clients 92 trial sites in the country. Australia-based CRO, Novotech, and Indian CRO, ETI Klinical, are teaming up to help meet the...

PGxHealth Allies with University of Pittsburgh to Determine Response to Anticancer...

FCGR3A’s role in predicting outcomes when IgG1 subclass of antibodies are used will be examined. PGxHealth and University of Pittsburgh are joining forces to research...

Hormone Replacement Therapy’s Effects on the Proteome Revealed

Changes are linked to coagulation and metabolic proteins, as reported in Genome Medicine. Scientists from the Fred Hutchinson Cancer Research Center have uncovered changes that...

Bayer Pays Ardea $35M for Its Anticancer MEK Inhibitors

Ardea is eligible to $372 million in success-based fees. Ardea Biosciences will receive $35 million up front from Bayer HealthCare in exchange for its MEK...

Adjuvant IL-7 Boosts Vaccine-Induced Immune Response to Tumors

IL-7 increased IL-6 and T helper type 17 cells in an animal model, according to Nature Medicine paper. An international team of scientists found that...
Scroll Up